Clinical trial
Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914
NCT00456924 · HRA Pharma, Industry · Completed
Key facts
| NCT number | NCT00456924 |
|---|---|
| Title | Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914 |
| Official title | Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium |
| Lead sponsor | HRA Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Contraception, Gynecologic Diseases |
| Intervention type | Drug |
| Interventions | VA2914 |
| Enrollment | 48 |
| Start date | Jan 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Apr 5, 2007 |
| Last update posted | Jun 17, 2010 |
| Countries | Belgium, France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: